Vertaling van "cancer risk " (Frans → Nederlands) :

TERMINOLOGIE

dépistage d'un cancer
kankerscreening

syndrome familial avec prédisposition aux cancers par mutations bialléliques de BRCA2
overgeërfde kankerpredispositie-syndroom door biallelische BRCA2-mutaties

générateur de système de traitement antimitotique du cancer par champ électrique alternatif
generator voor systeem voor antimitotische kankerbehandeling met wisselend elektrisch veld

jeu de transducteurs de système de traitement antimitotique de cancer par champ électrique alternatif
'array transducer' voor systeem voor antimitotische kankerbehandeling met wisselend elektrisch veld

cancer du côlon héréditaire non polyposique
erfelijke nonpolyposis colorectale kanker

système d’électrothérapie du cancer
elektrosysteem voor kankertherapie

syndrome de prédisposition au cancer-oligodontie
autosomaal dominante ectodermale dysplasie, kankerpredispositiesyndroom

syndrome héréditaire de prédisposition au cancer de l'ovaire
erfelijke plaatsspecifieke eierstokkanker-syndroom

syndrome héréditaire de prédisposition au cancer du sein et de l'ovaire
erfelijk borst- en ovariumkanker-syndroom

cancer papillaire rénal héréditaire
erfelijk papillair niercelcarcinoom

IN-CONTEXT TRANSLATIONS

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

30. Lippman SM , Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
30.Lippman SM , Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

28. Law J, Faulkner K, Young KC. Risk factors for induction of breast cancer by X-rays and their implications for breast screening.
27. Law J, Faulkner K, Young KC. Risk factors for induction of breast cancer by X-rays and their implications for breast screening.

29. Law J, Faulkner K. Concerning the relationship between benefit and radiation risk, and cancers detected and induced, in a breast screening programme.
28. Law J, Faulkner K. Concerning the relationship between benefit and radiation risk, and cancers detected and induced, in a breast screening programme.

(Narod 2002) Narod SA, Dubé MP, Klijn J et al. Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation
(Narod 2002) Narod SA, Dubé MP, Klijn J et al. Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. J Natl

U.S. Food and Drug Adminstration. Drug Safety Communication: 5-alpha reductase-inhibitors may increase the risk of a more serious form of prostate cancer.
FDA Drug Safety and Availibility Information, June 9, 2011. [http ...]

(Hannaford 2007) Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from
(Hannaford 2007) Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College

cancer in Finland: Intrauterine system carries a risk as well.
Finland: Intrauterine system carries a risk as well.

13. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.
12. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.

(Fernandez 2001) Fernandez E, La Vecchia C, Balducci A et al. Oral contraceptives and colorectal cancer risk: a meta-analysis.
(FSRH POI 2009) Faculty of Sexual and Reproductive Health Care (Royal College of Obstetricians and Gynaecologists).